地西他滨桥接异基因造血干细胞移植治疗儿童难治性恶性血液病的安全性评估  

The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies

作　　者：范丽艳 胡绍燕[1] 肖佩芳[1] 卢俊[1] 李捷[1] 姚艳华[1] 凌婧[1] 孔令军[1] 刘虎 卞馨妮 Fan Liyan;Hu Shaoyan;Xiao Peifang;Lu dun;Li die;Yao Yanhua;Ling Jing;Kong Lingjun;Liu Hu;Bian Xinni(Department of Hematology,Children＇s Hospital of Soochow University,Suzhou 215003,China)

机构地区：[1]苏州大学附属儿童医院血液科,215003

出　　处：《中华内科杂志》2018年第9期679-682,共4页Chinese Journal of Internal Medicine

基　　金：国家自然科学基金（81770193）;基于精准医学模式建立儿童急性髓细胞白血病整体化规范化个体化诊疗体系（LCZX201507）;苏州市儿童白血病重点实验室（SZS201615）;江苏省创新团队（CXTDA2017014）

摘　　要：评估难治性恶性血液病患儿在造血干细胞移植前使用地西他滨桥接预处理方案的安全性.本研究中11例患儿全部成功植入,最主要的不良反应为血液学毒性反应.所有患儿均未发生感染,无药物性肝损害及肾功能损害.大部分患儿发生Ⅰ～Ⅱ度胃肠道反应.1例发生超急性移植物抗宿主病,并于移植后61d因脑出血死亡,其余10例患儿至随访截止时间均存活.地西他滨桥接预处理方案在难治性恶性血液病患儿的异基因造血干细胞移植中是安全的.The safety of decitabine as bridging treatment before allogeneic hematopoietic stem cell transplantation （allo-HSCT） in children with refractory hematological malignancies was evaluated.All 11 cases succeeded in hematopoietic reconstitution.The main adverse reaction was hematological toxicity.Neither did infections occur,nor drug-induced liver damage and renal impairment during decitabine administration.Most cases showed grade Ⅰ-Ⅱ gastrointestinal adverse events.One case was diagnosed as severe acute graft versus host disease and died of intracranial hemorrhage on day 61 after allo-HSCT.The other 10 patients survived.Decitabine bridge is a safe regimen before allo-HSCT in children with refractory hematological malignancies.

关 键 词：地西他滨 异基因造血干细胞移植 儿童 桥接 安全性 

分 类 号：R733[医药卫生—肿瘤]